Phase 1/2 AVZO-1418 trial of investigational tyrosine kinase inhibitor

This Phase 1/2 study evaluates safety, tolerability, pharmacokinetics, and antitumor activity of AVZO-1418, an investigational tyrosine kinase inhibitor, administered intravenously as a monotherapy and in combination with labeled agents in patients with locally advanced or metastatic epithelial solid tumors. It is designed to identify the maximum tolerated dose in a dose-finding phase and to explore expansion cohorts for preliminary efficacy, marking the first clinical evaluation of AVZO-1418, sponsored by Avenzo Therapeutics, Inc.